Table 1 Characteristics of NSCLC patients who received neoadjuvant chemotherapy (NCT) or did not receive NCT (non-NCT) (N = 112)
N (%) | |||
|---|---|---|---|
Characteristic | Category | non-NCT (n = 61) | NCT (n = 51) |
Age | Median | 62 years | 65 years |
Sex | Female | 22 (36) | 22 (43) |
Male | 39 (64) | 29 (57) | |
Tobacco history | No | 3 (5) | 6 (12) |
Yes | 58 (95) | 45 (88) | |
Smoking status | Never | 3 (5) | 6 (12) |
Former | 28 (46) | 14 (28) | |
Current | 30 (49) | 31 (60) | |
Tumor size pretreatment (CT scan) | Median | – | 4.50 cm |
Tumor size posttreatment (Pathology)a | Median | 4.50 cm | 4.10 cm |
Tumor statusb | T1 | 4 (6) | 5 (10) |
T2 | 25 (41) | 23 (44) | |
T3 | 23 (38) | 13 (26) | |
T4 | 9 (15) | 10 (20) | |
Nodal statusb | N0 | 10 (16) | 7 (16) |
N1 | 18 (29) | 11 (18) | |
N2 | 33 (54) | 33 (66) | |
AJCC stageb | II | 7 (12) | 5 (8) |
III | 54 (88) | 46 (92) | |
Histology | ADC | 33 (54) | 31 (60) |
SCC | 28 (46) | 20 (40) | |
Neoadjuvant chemotherapy | Carboplatin/paclitaxel | – | 23 (45) |
Carboplatin/pemetrexed | – | 10 (20) | |
Cisplatin/othersc | – | 18 (35) | |
Adjuvant therapyd | No | 22 (36) | 11 (20) |
Yes | 39 (64) | 32 (64) | |
Vital status | Alive | 24 (39) | 13 (26) |
Dead | 37 (61) | 38 (74) | |
Overall survival | Median | 34 months | 21 months |